NASDAQ · YDES
Healthcare · Biotechnology
$4.69
Down-$0.10 (-2.00%)
Updated Aug 22, 2026, 6:59 AM
SID Score
4.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
YDES closed at $4.69 after 21 trading sessions, up 109.38% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $4.56 | $5.00 | $4.40 | $4.69 | 36.01K |
| Aug 20, 2026 | $4.39 | $4.99 | $4.0091 | $4.7858 | 105.12K |
| Aug 19, 2026 | $3.94 | $4.55 | $3.6001 | $4.47 | 83.94K |
| Aug 18, 2026 | $3.50 | $4.00 | $3.38 | $3.98 | 87.78K |
| Aug 17, 2026 | $3.11 | $3.40 | $2.79 | $3.37 | 64.6K |
| Aug 14, 2026 | $2.76 | $3.2399 | $2.415 | $2.98 | 73.61K |
| Aug 13, 2026 | $2.69 | $2.77 | $2.39 | $2.51 | 16.31K |
| Aug 12, 2026 | $2.79 | $2.80 | $2.58 | $2.60 | 22.05K |
| Aug 11, 2026 | $2.54 | $2.75 | $2.50 | $2.73 | 21.09K |
| Aug 10, 2026 | $2.275 | $2.57 | $2.1701 | $2.505 | 35.35K |
| Aug 7, 2026 | $2.55 | $2.5583 | $2.23 | $2.295 | 27.71K |
| Aug 6, 2026 | $2.35 | $2.49 | $2.21 | $2.3641 | 20.08K |
| Aug 5, 2026 | $2.25 | $2.395 | $2.25 | $2.25 | 23.96K |
| Aug 4, 2026 | $2.28 | $2.435 | $2.28 | $2.32 | 5.5K |
| Aug 3, 2026 | $2.35 | $2.46 | $2.21 | $2.30 | 142.89K |
| Jul 31, 2026 | $2.35 | $2.38 | $2.16 | $2.17 | 10.13K |
| Jul 30, 2026 | $2.26 | $2.38 | $2.11 | $2.20 | 28.82K |
| Jul 29, 2026 | $2.31 | $2.31 | $2.10 | $2.269 | 14.62K |
| Jul 28, 2026 | $2.29 | $2.60 | $2.18 | $2.30 | 42.64K |
| Jul 27, 2026 | $2.21 | $2.37 | $2.17 | $2.29 | 25.94K |
| Jul 24, 2026 | $2.44 | $2.44 | $1.96 | $2.24 | 83.14K |
The latest Smart Investors Daily articles mentioning YDES.
YDES research
Company profile and research snapshot.
YD Bio Ltd is a biopharmaceutical company focusing on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Jul 7, 2026
Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 34.7% to $0.96 during Tuesday's after-market session. The company's market cap stands at $2.0 million. Ironwood Pharmaceuticals (NASDAQ:IRWD)
ChartMill · Jul 7, 2026
Unusual volume stocks in Tuesday's session
Benzinga · Jul 7, 2026
Gainers Crinetics Pharmaceuticals (NASDAQ:CRNX) shares moved upwards by 98.7% to $83.53 during Tuesday's regular session. The company's market cap stands at $4.4 billion. Tvardi Therapeutics (NASDAQ:TVRD)
Benzinga · Jul 7, 2026
Gainers Crinetics Pharmaceuticals (NASDAQ:CRNX) stock increased by 98.9% to $83.59 during Tuesday's pre-market session. The market value of their outstanding shares is at $4.4 billion. Bluejay Diagnostics
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning YDES.
